A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice

What this study is about

The main aim of the study to describe the characteristics of participants with asthma across the spectrum of disease severity, including sociodemographic and clinical characteristics, treatment and disease burden, biomarkers, and both disease-specific and generic health-related quality of life. The study consists of two parts: a cross-sectional study, and a prospective follow-up evaluate changes in disease trajectories in participants with asthma.

Who can join (things the study team will check)

✅ You may be able to join if…

• Age 6 years and older, at the time of signing the informed consent
• Physician diagnosis of asthma for at least 12 months
• Existing treatment with low, medium, or high dose ICS and other asthma therapies as reflected in GINA 2-5 steps
• Participant or legally authorized representative (where applicable) has consented to participate Applicable for Part 2 participants:
• Age 18 years and older, at the time of signing the informed consent.
• Physician diagnosis of asthma for at least 12 months
• Existing treatment with low or medium ICS and other asthma therapies as reflected in GINA 2-4 steps
• Participant or legally authorized representative (where applicable) has consented to participate
• Participants must meet the criteria for at least one of the cohorts below: A) Asthma control cohorts
• ACQ-5 >= 1.5
• ACQ-5 < 1.5 (B) Type-2 biomarker cohorts
• Elevated T2 biomarkers (B1: Type-2-high cohort)
• Low T2 biomarkers (B2: Type-2-low cohort) Participants are excluded from the study if any of the following criteria apply (applicable for both Part 1 and Part 2 participants):
• Current diagnosis of chronic obstructive pulmonary disease (COPD) or congestive heart failure
• Participants with moderate/severe cognitive impairment.
• Participants with moderate/severe cardiac disease.
• Participants on immunosuppressive medication for a chronic condition.
• Participation in other interventional and noninterventional clinical study (currently or in the past 3 months) The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Where this trial is running

• Chandler Clinical Trials - Site Number: 840106, Chandler, Arizona, United States
• Del Sol Research Management, LLC - Mesa - Site Number: 840123, Mesa, Arizona, United States
• Sun City Clinical Trials - Elite - Site Number: 840120, Sun City, Arizona, United States
• FOMAT - Huntington Asthma & Allergy Center - Site Number: 840158, California City, California, United States
• Imax Clinical Trials - Site Number: 840109, La Palma, California, United States
• Newport Native MD, Inc. - Site Number: 840101, Newport Beach, California, United States
• Pasadena Clinical Trials - Site Number: 840116, Pasadena, California, United States
• Valiance Clinical Research (JPJ Research) - Site Number: 840135, Tarzana, California, United States
• Clinical Research of California - Site Number: 840145, Walnut Creek, California, United States
• Cornerstone Research Institute, LLC - Site Number: 840152, Altamonte Springs, Florida, United States
• 3SYNC Research - Boca Raton - Site Number: 840148, Boca Raton, Florida, United States
• Meris Clinical Research - Site Number: 840167, Brandon, Florida, United States

+ 42 more sites.

Who to contact

Trial Transparency email recommended-Toll free for US & Canada · 800-633-1610 · Contact-US@sanofi.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07556159.